Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer.

Trial Profile

Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2015

At a glance

  • Drugs Fulvestrant (Primary) ; Vandetanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jul 2015 Status changed from discontinued to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 10 Mar 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top